论文部分内容阅读
目的观察应用替格瑞洛治疗急性心肌梗死的临床疗效及出血风险。方法 40例急性心肌梗死患者,随机分为氯吡格雷组和替格瑞洛组,各20例。观察两组患者主要不良心血管事件和治疗期间出血并发症发生情况。结果氯吡格雷组患者主要不良心血管事件发生率为40%,显著高于替格瑞洛组的10%,差异有统计学意义(P<0.05);氯吡格雷组和替格瑞洛组出血发生率分别为10%、5%,比较差异无统计学意义(P>0.05)。结论应用替格瑞洛治疗急性心肌梗死,可减少主要不良心血管事件的发生,而不增加严重出血的并发症。
Objective To observe the clinical efficacy and risk of bleeding of ticagrelor in the treatment of acute myocardial infarction. Methods Forty patients with acute myocardial infarction were randomly divided into clopidogrel group and ticagrelor group, 20 cases each. The main adverse cardiovascular events and the occurrence of bleeding complications during the two groups were observed. Results The incidence rate of major adverse cardiovascular events in clopidogrel group was 40%, which was significantly higher than that in ticagrelor group (P <0.05), and there was a significant difference between the clopidogrel group and ticagrelor group Bleeding rates were 10%, 5%, respectively, with no significant difference (P> 0.05). Conclusion Ticagrelor in the treatment of acute myocardial infarction can reduce the incidence of major adverse cardiovascular events without increasing the complications of severe bleeding.